PL2797581T3 - Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu - Google Patents

Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu

Info

Publication number
PL2797581T3
PL2797581T3 PL12808662T PL12808662T PL2797581T3 PL 2797581 T3 PL2797581 T3 PL 2797581T3 PL 12808662 T PL12808662 T PL 12808662T PL 12808662 T PL12808662 T PL 12808662T PL 2797581 T3 PL2797581 T3 PL 2797581T3
Authority
PL
Poland
Prior art keywords
aminoisoindoline
methanesulfonyl
dione
ethoxy
acetyl
Prior art date
Application number
PL12808662T
Other languages
English (en)
Inventor
Sreenivas S. Bhat
Michael T. Kelly
Original Assignee
Amgen (Europe) GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459206&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2797581(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen (Europe) GmbH filed Critical Amgen (Europe) GmbH
Publication of PL2797581T3 publication Critical patent/PL2797581T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
PL12808662T 2011-12-27 2012-12-26 Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu PL2797581T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580626P 2011-12-27 2011-12-27
EP12808662.6A EP2797581B1 (en) 2011-12-27 2012-12-26 Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
PCT/US2012/071623 WO2013101810A1 (en) 2011-12-27 2012-12-26 Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione

Publications (1)

Publication Number Publication Date
PL2797581T3 true PL2797581T3 (pl) 2020-10-05

Family

ID=47459206

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12808662T PL2797581T3 (pl) 2011-12-27 2012-12-26 Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu

Country Status (33)

Country Link
US (2) US20130164376A1 (pl)
EP (2) EP3756650A1 (pl)
JP (1) JP6161629B2 (pl)
KR (3) KR102035362B1 (pl)
CN (1) CN104136003A (pl)
AU (1) AU2012362562B2 (pl)
BR (1) BR112014015923B1 (pl)
CA (1) CA2861594A1 (pl)
CL (1) CL2014001726A1 (pl)
CO (1) CO7000777A2 (pl)
CR (1) CR20140314A (pl)
CY (1) CY1123174T1 (pl)
DK (1) DK2797581T3 (pl)
EA (1) EA027801B1 (pl)
EC (1) ECSP14007965A (pl)
ES (1) ES2799448T3 (pl)
HK (1) HK1202056A1 (pl)
HR (1) HRP20200825T1 (pl)
HU (1) HUE050327T2 (pl)
IL (1) IL233296B (pl)
LT (1) LT2797581T (pl)
MX (2) MX2014007878A (pl)
NI (1) NI201400068A (pl)
PE (1) PE20142318A1 (pl)
PH (1) PH12014501495A1 (pl)
PL (1) PL2797581T3 (pl)
PT (1) PT2797581T (pl)
RS (1) RS60415B1 (pl)
SG (2) SG11201403564YA (pl)
SI (1) SI2797581T1 (pl)
UA (1) UA113750C2 (pl)
WO (1) WO2013101810A1 (pl)
ZA (1) ZA201404629B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2765993B1 (en) 2011-09-14 2020-05-20 Amgen (Europe) GmbH Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide
JP6161629B2 (ja) 2011-12-27 2017-07-12 セルジーン コーポレイション （＋）−２−［１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−４−アセチルアミノイソインドリン−１，３−ジオンの製剤
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
EP3174999A1 (en) 2014-07-29 2017-06-07 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
WO2017004122A1 (en) * 2015-06-30 2017-01-05 Genentech, Inc. Immediate-release tablets containing a drug and processes for forming the tablets
CZ20165A3 (cs) * 2016-01-06 2017-07-19 Zentiva, K.S. Způsoby přípravy amorfního apremilastu
US20190175491A1 (en) 2016-06-15 2019-06-13 Torrent Pharmaceuticals Limited Topical compositions of apremilast
CA3138473A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
ES2823927B2 (es) * 2019-11-07 2022-01-18 Beijing Enbiwo Biological Tech Co Ltd Composición en tamaño micrométrico y su uso como agente coadyuvante de alcaloides vegetales
KR20220047105A (ko) 2020-10-08 2022-04-15 주식회사 엔비피헬스케어 아프레밀라스트를 함유하는 약학 조성물
CN112245403B (zh) * 2020-10-23 2022-04-22 杭州朱养心药业有限公司 磷酸二酯酶-4抑制剂及其口服固体组合物
EP4183389A1 (en) 2021-11-18 2023-05-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apremilast
WO2023118043A1 (en) 2021-12-22 2023-06-29 Biohorm, S.L. Pharmaceutical compositions of apremilast

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
SK9199A3 (en) 1996-07-24 1999-07-12 Celgene Corp 2,6-dioxopiperidines, pharmaceutical composition them containing and their use
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
CN1511420A (zh) 2001-11-09 2004-07-07 松下电器产业株式会社 运动图像编码方法和装置
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
BRPI0417186A (pt) 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
ZA200607799B (en) 2004-03-22 2008-06-25 Celgene Corp Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
WO2005105088A2 (en) 2004-04-23 2005-11-10 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
BRPI0517481A (pt) 2004-11-12 2008-10-14 Celgene Corp método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
WO2006058008A1 (en) 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
CA2588990A1 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
MX2007009812A (es) * 2005-02-15 2007-10-23 Wyeth Corp Formulaciones en tableta de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico oralmente biodisponibles.
EP1858514B1 (en) * 2005-03-17 2014-11-26 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
WO2006111980A2 (en) 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
EP1928492B1 (en) 2005-09-01 2011-02-23 Celgene Corporation Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
SG10201402158VA (en) 2009-02-10 2014-07-30 Celgene Corp Methods Of Using And Compositions Comprising PDE4 Modulators For Treatment, Prevention And Management Of Tuberculosis
AU2010319377B2 (en) 2009-11-13 2014-10-23 Astrazeneca Ab Immediate release tablet formulations
CN103442698B (zh) * 2010-12-16 2016-10-05 细胞基因公司 难溶性药物的控释口服剂量形式及其用途
JP6161629B2 (ja) 2011-12-27 2017-07-12 セルジーン コーポレイション （＋）−２−［１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−４−アセチルアミノイソインドリン−１，３−ジオンの製剤

Also Published As

Publication number Publication date
HK1202056A1 (en) 2015-09-18
JP2015506356A (ja) 2015-03-02
NI201400068A (es) 2016-01-28
US20210093573A1 (en) 2021-04-01
SG10201605251VA (en) 2016-08-30
LT2797581T (lt) 2020-07-10
EP2797581A1 (en) 2014-11-05
MX2020005145A (es) 2020-08-17
CY1123174T1 (el) 2021-10-29
KR20190120418A (ko) 2019-10-23
AU2012362562B2 (en) 2017-11-02
BR112014015923A8 (pt) 2017-07-04
MX2014007878A (es) 2015-03-23
CO7000777A2 (es) 2014-07-21
JP6161629B2 (ja) 2017-07-12
SI2797581T1 (sl) 2020-08-31
EA201491292A1 (ru) 2014-11-28
IL233296B (en) 2018-11-29
RS60415B1 (sr) 2020-07-31
KR102035362B1 (ko) 2019-10-22
NZ626615A (en) 2016-08-26
CA2861594A1 (en) 2013-07-04
PH12014501495B1 (en) 2014-09-22
UA113750C2 (xx) 2017-03-10
AU2012362562A1 (en) 2014-07-17
US20130164376A1 (en) 2013-06-27
DK2797581T3 (da) 2020-07-20
ES2799448T3 (es) 2020-12-17
CN104136003A (zh) 2014-11-05
HRP20200825T1 (hr) 2020-08-07
CR20140314A (es) 2014-10-28
ECSP14007965A (es) 2015-11-30
EA027801B1 (ru) 2017-09-29
PH12014501495A1 (en) 2014-09-22
HUE050327T2 (hu) 2020-11-30
IL233296A0 (en) 2014-08-31
EP2797581B1 (en) 2020-05-06
CL2014001726A1 (es) 2014-11-14
BR112014015923A2 (pt) 2017-06-13
WO2013101810A1 (en) 2013-07-04
PE20142318A1 (es) 2015-01-16
BR112014015923B1 (pt) 2022-02-01
KR102232154B1 (ko) 2021-03-25
KR20140108707A (ko) 2014-09-12
KR20210033073A (ko) 2021-03-25
PT2797581T (pt) 2020-06-18
EP3756650A1 (en) 2020-12-30
SG11201403564YA (en) 2014-07-30
ZA201404629B (en) 2017-08-30

Similar Documents

Publication Publication Date Title
HK1202056A1 (en) Formulations of ()-2-[1-(3-ethoxy-4-methoxy-phenyl)-2- methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione ()-2-[1-(3--4--)-2--]-4- -13-
HK1199255A1 (en) Indazole compounds, compositions and methods of use
EP2720631A4 (en) SURGICAL ALIGNMENT USING REFERENCES
IL230836A (en) Multi-part disinfectant system
SG10201605172RA (en) Compositions and methods for selectively etching titanium nitride
ZA201403969B (en) 2-(substituted-phenyl)=cyclopentane-1,3-dione compounds, and derivatives thereof
EP2796109A4 (en) DENTAL MEMBRANE
ZA201402148B (en) Coolant formulations
ZA201306016B (en) Bendamustine formulations
SI2753311T1 (sl) Formulacije antioksidanta
HRP20190186T1 (hr) Nove formulacije (trimetoksifenilamino)pirimidinila
GB201114725D0 (en) Ophthalmic formulations
HK1213785A1 (zh) 血管緊張素的口服製劑
EP2680774A4 (en) FLUORESCENT HANDPIECE
GB201110278D0 (en) Formulations
TH1401003680A (th) สูตรผสมของ (+)-2-[1-(3-อีธอกซิ-4-เมธอกซิ-ฟีนิล)-2-มีเธนซัลโฟนิล-เอธิล]-4- อะซิติลอะมิโนไอโซอินโดไลน์-1,3-ไดโอน
GB201111013D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201104049D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201102795D0 (en) Formulations
GB201109725D0 (en) Push-pull outlet